Red flags and safety concerns

TL;DR

• Call emergency services for major or increasing haemoptysis, severe breathlessness, stridor, cyanosis, syncope, new focal neurological deficit, seizure, rapidly progressive weakness, chest pain with instability, or suspected sepsis. Do not drive an unstable person to clinic.
• Central LUSC can obstruct a main airway, bleed, cavitate, infect behind an obstruction, or invade major vessels. Tumour diameter alone does not convey this risk.
• Fever during cytotoxic therapy is neutropenic sepsis until assessed. Obtain cultures and laboratory evaluation promptly, but do not delay empiric antibiotics in an unstable patient.
• New cough, dyspnoea, diarrhoea, weakness, headache, confusion, chest pain, or jaundice during or after checkpoint immunotherapy may be immune toxicity. Hold treatment while significant toxicity is evaluated; immune adverse events can occur after the last dose.
• Pneumonitis has competing causes—immune therapy, radiation, infection, tumour, oedema, embolus—and pattern recognition alone is insufficient. Infection and pulmonary embolism must remain in the differential.
• Every treatment plan needs a written 24-hour contact route, medication list, anticoagulation status, steroid plan, and explicit thresholds for emergency versus same-day oncology review.

Triage by action window

This page supports safety planning; it does not replace local emergency protocols or individual clinical judgment.

Emergency response now

Red flag	Immediate concern	First priorities
Large-volume, rapidly increasing, or airway-compromising haemoptysis	Asphyxiation and haemodynamic collapse	Emergency services; airway/oxygenation; bleeding side down if known and feasible; reverse correctable coagulopathy; interventional pulmonology/radiology/thoracic surgery
Stridor, silent hemithorax, cyanosis, inability to speak full sentences	Critical central-airway obstruction	Airway-skilled team; avoid unplanned sedation; urgent bronchoscopy/local therapy
New unilateral weakness, aphasia, seizure, reduced consciousness	Brain metastasis complication, stroke, haemorrhage, seizure	Emergency neurological imaging and stabilization
New back pain plus weakness, sensory level, saddle anaesthesia, or bladder/bowel change	Metastatic spinal-cord/cauda-equina compression	Urgent MRI pathway, corticosteroid/local definitive treatment per protocol
Syncope, shock, distended neck veins, severe orthopnoea	Tamponade, massive pulmonary embolism, arrhythmia, SVC complication	Resuscitation and urgent bedside cardiopulmonary assessment
Fever with hypotension, confusion, rigors, or severe neutropenia	Sepsis/febrile neutropenia	Cultures/lactate/labs without antibiotic delay; IV broad-spectrum therapy and admission
Chest pain, arrhythmia, troponin rise, or new heart block on immunotherapy	Immune myocarditis/overlap myositis	Hold immunotherapy; emergency ECG/troponin/echo and specialist treatment

Same-day clinical assessment

Signal	Why same day
Any new haemoptysis in a central/cavitating tumour or while anticoagulated	Sentinel bleeding may precede a major event
New/worsening cough, dyspnoea, resting desaturation, or fever	Pneumonitis, infection, embolus, effusion, oedema, obstruction
Face/neck/arm swelling, venous distension, headache worse bending forward	Superior vena cava obstruction; airway/cerebral compromise can evolve
Persistent vomiting, severe diarrhoea, blood in stool, or abdominal pain on checkpoint therapy	Colitis, dehydration, perforation, adrenal crisis
Severe headache, visual change, profound weakness, hypotension, confusion	Hypophysitis, adrenal insufficiency, severe electrolyte disturbance, CNS disease
New jaundice, dark urine, or marked right-upper-quadrant pain	Immune hepatitis, obstruction, infection, progression
Reduced urine output, severe thirst, constipation, confusion	Hypercalcaemia, acute kidney injury, tumour lysis, dehydration
Painful swollen leg or unexplained tachycardia/dyspnoea	Cancer-associated thrombosis or pulmonary embolism
New drainage, fever, subcutaneous air, or sudden dyspnoea after lung surgery	Empyema, air leak, bronchopleural fistula, pneumonia, embolus

Haemoptysis

LUSC is overrepresented among central, cavitating, and bleeding lung tumours. Severity is defined by physiological consequence and airway threat, not a universally reliable volume threshold. Even a modest volume can be fatal if the airway cannot clear it. Reviews emphasize early airway protection, localisation, bronchoscopy, CT angiography, bronchial-artery embolization, and selected surgery ([PMID 35166503](https://pubmed.ncbi.nlm.nih.gov/35166503/){target="_blank" rel="noopener"}; [PMID 31374211](https://pubmed.ncbi.nlm.nih.gov/31374211/){target="_blank" rel="noopener"}; [PMID 32862418](https://pubmed.ncbi.nlm.nih.gov/32862418/){target="_blank" rel="noopener"}).

Risk amplifiers

• central or cavitating tumour abutting pulmonary or bronchial vessels;
• prior thoracic radiotherapy or antiangiogenic therapy;
• anticoagulant or antiplatelet use, thrombocytopenia, liver dysfunction;
• necrosis, infection, aspergillus colonisation, or fistula;
• recent biopsy, bronchoscopy, stent, or ablative procedure;
• pulmonary hypertension or limited reserve.

Do not use bleeding volume alone to reassure. Record colour, estimated amount, frequency, clot, positional trigger, oxygenation, haemodynamics, medications, platelet count/coagulation, and tumour-vessel anatomy. Life-threatening bleeding often kills by airway flooding rather than exsanguination ([PMID 26873518](https://pubmed.ncbi.nlm.nih.gov/26873518/){target="_blank" rel="noopener"}).

Malignant central-airway obstruction

Warning features include stridor, monophonic wheeze, positional dyspnoea, recurrent same-lobe pneumonia, lobar collapse, difficulty clearing secretions, and rapidly increasing oxygen need. The 2025 CHEST guideline supports a multidisciplinary approach with therapeutic bronchoscopy as an adjunct to systemic therapy and/or local radiation for symptomatic central-airway obstruction ([PMID 39029785](https://pubmed.ncbi.nlm.nih.gov/39029785/){target="_blank" rel="noopener"}). Flexible bronchoscopy guidance covers diagnostic and therapeutic techniques but airway compromise may require rigid bronchoscopy and anaesthesia expertise ([PMID 22003155](https://pubmed.ncbi.nlm.nih.gov/22003155/){target="_blank" rel="noopener"}).

Obstruction type	Potential approach	Safety issue
Endoluminal tumour	Mechanical debulking, thermal or cryo techniques	Bleeding, fire with some thermal modalities/high oxygen, perforation
Extrinsic compression	Airway stent, radiation/systemic response	Migration, mucus plugging, granulation, fistula
Mixed	Debulking plus stent and oncologic therapy	Combines both risk sets
Post-obstructive infection	Drain/restore airway plus antimicrobials	Antibiotics alone may fail without source control

Sedation can convert a partially patent airway into complete obstruction. Procedures should occur where immediate airway rescue is available.

Superior vena cava obstruction

Facial, neck, or upper-limb swelling; venous collaterals; dyspnoea; cough; head pressure; visual symptoms; and worsening when supine suggest SVC obstruction. A scoping review found heterogeneous evidence and practice across radiation, systemic treatment, endovascular stenting, and anticoagulation ([PMID 37146753](https://pubmed.ncbi.nlm.nih.gov/37146753/){target="_blank" rel="noopener"}). Contemporary management prioritizes anatomical cause, symptom severity, tissue needs, thrombus, and expected tumour response ([PMID 38600814](https://pubmed.ncbi.nlm.nih.gov/38600814/){target="_blank" rel="noopener"}; [PMID 35004083](https://pubmed.ncbi.nlm.nih.gov/35004083/){target="_blank" rel="noopener"}).

Airway compromise, cerebral oedema, or haemodynamic instability is an emergency. In a stable patient without diagnosis, obtain tissue before empiric radiation when feasible. Stenting can provide rapid relief but carries bleeding, migration, thrombosis, rupture, and tamponade risks ([PMID 26622107](https://pubmed.ncbi.nlm.nih.gov/26622107/){target="_blank" rel="noopener"}). Thrombus does not automatically settle anticoagulation; bleeding risk and planned procedures must be integrated ([PMID 30255420](https://pubmed.ncbi.nlm.nih.gov/30255420/){target="_blank" rel="noopener"}).

Neurological emergencies

Brain metastases

New headache, seizure, focal deficit, gait change, vomiting, personality/cognitive change, or altered consciousness requires urgent evaluation. The ASCO/SNO/ASTRO guideline recommends local therapy for symptomatic brain metastases regardless of systemic therapy used ([PMID 34932393](https://pubmed.ncbi.nlm.nih.gov/34932393/){target="_blank" rel="noopener"}). Corticosteroids treat oedema but can worsen infection, hyperglycaemia, proximal weakness, mood, and checkpoint efficacy; use the minimum effective course with a plan.

Metastatic spinal-cord compression

Back pain may precede weakness. Night pain, pain on coughing/straining, radicular pain, sensory change, gait difficulty, and sphincter dysfunction are red flags. Outcome depends strongly on neurological function at treatment; do not wait for paralysis. Reviews and guideline assessments emphasize urgent whole-spine MRI, corticosteroids where appropriate, stability assessment, and prompt surgery/radiation decision ([PMID 20577931](https://pubmed.ncbi.nlm.nih.gov/20577931/){target="_blank" rel="noopener"}; [PMID 24619048](https://pubmed.ncbi.nlm.nih.gov/24619048/){target="_blank" rel="noopener"}; [PMID 24336849](https://pubmed.ncbi.nlm.nih.gov/24336849/){target="_blank" rel="noopener"}).

Metabolic and vascular emergencies

Hypercalcaemia of malignancy

Squamous tumours can produce parathyroid-hormone-related peptide. Thirst, polyuria, constipation, nausea, weakness, confusion, shortened QT interval, and kidney injury may be the first clues. Corrected total calcium can mislead with abnormal albumin; ionized calcium may be needed. The Endocrine Society guideline supports IV hydration tailored to cardiac/renal status and antiresorptive therapy, with calcitonin for selected severe cases because of rapid but transient effect ([PMID 36545746](https://pubmed.ncbi.nlm.nih.gov/36545746/){target="_blank" rel="noopener"}). Treat the tumour and avoid exacerbating drugs when possible.

Hyponatraemia and adrenal failure

Although SIADH is classically linked to small-cell carcinoma, hyponatraemia in LUSC still occurs through drugs, infection, nausea, volume depletion, adrenal metastasis, or immune hypophysitis/adrenalitis. Headache, vomiting, confusion, seizure, or severe biochemical abnormality is urgent. Management depends on tonicity, chronicity, symptoms, and volume state; rapid overcorrection risks osmotic demyelination. Lung-cancer-specific review emphasizes cause-directed assessment rather than assuming SIADH ([PMID 29344107](https://pubmed.ncbi.nlm.nih.gov/29344107/){target="_blank" rel="noopener"}).

Venous thromboembolism

Cancer, hospitalization, surgery, systemic therapy, and central lines raise thrombosis risk. New dyspnoea, pleuritic pain, tachycardia, syncope, hypoxaemia, or unilateral limb swelling needs prompt assessment. ASCO guidance addresses thromboprophylaxis and treatment selection across ambulatory, hospitalized, surgical, and established-VTE settings ([PMID 37075273](https://pubmed.ncbi.nlm.nih.gov/37075273/){target="_blank" rel="noopener"}). Anticoagulation choice must account for haemoptysis, brain disease, thrombocytopenia, renal function, drug interactions, procedures, and patient preference.

Cytotoxic-therapy safety

Fever and neutropenia

Fever after chemotherapy is time critical. The ASCO/IDSA outpatient guideline uses formal risk assessment; selected stable low-risk adults may receive outpatient therapy only after initial evaluation, prompt antibacterial treatment, observation, and reliable follow-up ([PMID 29461916](https://pubmed.ncbi.nlm.nih.gov/29461916/){target="_blank" rel="noopener"}). Unstable physiology, pneumonia, organ dysfunction, uncontrolled symptoms, or poor access to rapid return argues against outpatient management.

Toxicity	Red flags	Prevention/monitoring
Neutropenic sepsis	Fever or hypothermia, rigors, hypotension, confusion	CBC nadir awareness, emergency card, growth-factor strategy when indicated
Thrombocytopenia	Haemoptysis, petechiae, melena, severe headache	CBC and bleeding review; anticoagulant coordination
Anaemia	Rest dyspnoea, chest pain, syncope	Trend haemoglobin; evaluate bleeding, haemolysis, nutrition, marrow disease
Taxane neuropathy	Falls, motor change, loss of fine function	Functional grading before each cycle; dose modification
Cisplatin renal/otologic injury	Oliguria, electrolyte loss, tinnitus/hearing change	Renal/electrolyte monitoring, hydration, audiology when relevant
Hypersensitivity	Wheeze, hypotension, angioedema during infusion	Stop infusion; emergency protocol; document culprit and rechallenge plan

Immune-checkpoint toxicity

ASCO guidance covers organ-specific grading, holding or discontinuing therapy, corticosteroids, additional immunosuppression, and rechallenge ([PMID 34724392](https://pubmed.ncbi.nlm.nih.gov/34724392/){target="_blank" rel="noopener"}). Toxicity can occur during treatment or months afterward; the emergency team must know the prior checkpoint agent.

Organ	Warning pattern	Essential exclusions/actions
Lung	New cough, dyspnoea, hypoxaemia, bilateral or focal infiltrates	Hold drug for significant symptoms; CT/oximetry; exclude infection, embolus, oedema, radiation change
Heart/muscle	Chest pain, dyspnoea, palpitations, weakness, ptosis/diplopia	ECG, troponin, CK, echo; myocarditis–myositis–myasthenia overlap can deteriorate rapidly
Gut	Persistent diarrhoea, blood, abdominal pain, fever	Stool infection tests; grade volume; image/endoscopy when indicated; perforation risk
Liver	Rising transaminases/bilirubin, jaundice	Exclude viral, obstructive, metastatic, alcohol/drug causes
Endocrine	Headache, fatigue, hypotension, polyuria, glucose change	Cortisol/ACTH, TSH/free T4, glucose/electrolytes; replace hormone before thyroid hormone if adrenal crisis possible
Nervous system	Weakness, sensory change, confusion, autonomic symptoms	Urgent neurology evaluation; exclude metastasis, stroke, infection, electrolytes
Kidney	Creatinine rise, sterile pyuria	Exclude obstruction, dehydration, sepsis, nephrotoxins
Skin	Blistering, mucosal lesions, widespread tenderness	Stop therapy and urgent dermatology/burn-level assessment for severe reactions

PD-1 pneumonitis can show organizing-pneumonia, ground-glass, hypersensitivity, or diffuse patterns; severity ranges from incidental imaging to respiratory failure ([PMID 27535979](https://pubmed.ncbi.nlm.nih.gov/27535979/){target="_blank" rel="noopener"}). Immune myocarditis is uncommon but can cause conduction block, ventricular arrhythmia, and death; troponin elevation with muscle or neurological symptoms warrants overlap-syndrome evaluation ([PMID 31960755](https://pubmed.ncbi.nlm.nih.gov/31960755/){target="_blank" rel="noopener"}; [PMID 30925516](https://pubmed.ncbi.nlm.nih.gov/30925516/){target="_blank" rel="noopener"}). Early high-intensity immunosuppression is sometimes required, and abatacept/ruxolitinib strategies remain specialist/emerging rather than routine ([PMID 36815259](https://pubmed.ncbi.nlm.nih.gov/36815259/){target="_blank" rel="noopener"}).

Radiation and postoperative hazards

Radiation pneumonitis typically occurs after a latency but timing and field distribution vary. International consensus supports integrating symptoms, oxygenation, CT pattern, dose distribution, pulmonary function, and infectious evaluation ([PMID 38788551](https://pubmed.ncbi.nlm.nih.gov/38788551/){target="_blank" rel="noopener"}). Recall pneumonitis and overlapping checkpoint therapy complicate attribution.

After resection, escalating breathlessness, fever, purulent sputum, atrial arrhythmia, calf swelling, or wound change requires prompt review. Bronchopleural fistula is uncommon but severe; neoadjuvant therapy has been studied as a risk factor in a meta-analysis of 14,912 patients ([PMID 27052116](https://pubmed.ncbi.nlm.nih.gov/27052116/){target="_blank" rel="noopener"}). Large registry analysis identifies operative and patient factors associated with fistula and respiratory failure ([PMID 30328066](https://pubmed.ncbi.nlm.nih.gov/30328066/){target="_blank" rel="noopener"}). Sudden continuous air leak, expectoration of fluid, empyema, or post-pneumonectomy change is an emergency.

Malignant pleural effusion commonly causes dyspnoea; ATS/STS/STR guidance supports symptom-directed thoracentesis, indwelling pleural catheter, or pleurodesis according to lung expansion, recurrence, and preference ([PMID 30272503](https://pubmed.ncbi.nlm.nih.gov/30272503/){target="_blank" rel="noopener"}). Rapidly recurring fluid, fever, loculation, or non-expanding lung alters the plan.

Medication and procedural safety checklist

• Record all anticoagulants, antiplatelets, corticosteroids, supplements, and over-the-counter drugs.
• Coordinate anticoagulation around biopsy, bronchoscopy, port, surgery, radiation procedures, and thrombocytopenia.
• Avoid bevacizumab in squamous NSCLC; review bleeding/fistula risk with any antiangiogenic drug.
• Verify renal function and hearing risk before cisplatin; neuropathy before taxanes; marrow reserve before cytotoxics.
• Screen hepatitis/TB/HIV or other infections as required before immunosuppression and some trials.
• Provide vaccination and infection-prevention advice appropriate to treatment and local policy.
• Give written immune-toxicity and neutropenic-fever cards with 24-hour numbers.
• Before discharge after airway intervention, document stent-clearance and mucus-plugging plan.
• Before opioid or sedative escalation in central obstruction, reassess ventilation risk.
• After starting high-dose steroids, plan glucose, infection, gastric/bone protection where appropriate, and taper ownership.

Safety-net handover template

Item	Record explicitly
Diagnosis	LUSC, stage/TNM edition, sites threatening airway/vessels/CNS
Current therapy	Agents, cycle/day, last dose, radiation field/date, surgery date
Expected nadir	Dates and growth-factor use
Immune exposure	Agent and last dose—even if months ago
Devices	Port, airway stent, pleural catheter, oxygen
Medicines	Anticoagulant/antiplatelet, steroid dose, insulin, opioids
Emergency thresholds	Fever definition, bleeding, oxygen, diarrhoea, neurological and cardiac symptoms
Contacts	24-hour oncology number, interventional pulmonology, trial team, local emergency service
Preferences	Resuscitation/advance-care documentation and chosen surrogate, where available

Open questions

1. Can imaging and circulating markers predict catastrophic haemoptysis before a sentinel bleed?
2. Which airway-obstruction interventions best preserve function while systemic therapy takes effect?
3. Can baseline lung imaging distinguish future immune from radiation pneumonitis risk?
4. What monitoring strategy detects checkpoint myocarditis early without excessive false positives?
5. How can rural patients receive equivalent time-to-antibiotic, airway, and immune-toxicity care?

Related pages

• Central-airway biology and presentation
• Staging
• Immunotherapy
• Chemotherapy and histology constraints
• Patient experience and advocacy

References

1. O'Gurek D, Choi HYJ. Hemoptysis: Evaluation and Management. Am Fam Physician. 2022;105(2):144-151. PMID 35166503
2. Davidson K, Shojaee S. Managing Massive Hemoptysis. Chest. 2020;157(1):77-88. PMID 31374211
3. Deshwal H, Sinha A, Mehta AC. Life-Threatening Hemoptysis. Semin Respir Crit Care Med. 2021;42(1):145-159. PMID 32862418
4. Cordovilla R, Bollo de Miguel E, Nuñez Ares A, Cosano Povedano FJ, Herráez Ortega I, Jiménez Merchán R. Diagnosis and Treatment of Hemoptysis. Arch Bronconeumol. 2016;52(7):368-77. PMID 26873518
5. Mahmood K, Frazer-Green L, Gonzalez AV, Shofer SL, Argento AC, Welsby I, et al. Management of Central Airway Obstruction: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025;167(1):283-295. PMID 39029785
6. Du Rand IA, Barber PV, Goldring J, Lewis RA, Mandal S, Munavvar M, et al. Summary of the British Thoracic Society guidelines for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax. 2011;66(11):1014-5. PMID 22003155
7. Wright K, Digby GC, Gyawali B, Jad R, Menard A, Moraes FY, et al. Malignant Superior Vena Cava Syndrome: A Scoping Review. J Thorac Oncol. 2023;18(10):1268-1276. PMID 37146753
8. Chow R, Simone CB 2nd, Rimner A. Management of malignant superior vena cava syndrome. Ann Palliat Med. 2024;13(3):620-626. PMID 38600814
9. Patriarcheas V, Grammoustianou M, Ptohis N, Thanou I, Kostis M, Gkiozos I, et al. Malignant Superior Vena Cava Syndrome: State of the Art. Cureus. 2022;14(1):e20924. PMID 35004083
10. Stevens DC, Butty S, Johnson MS. Superior Vena Cava Rupture and Cardiac Tamponade Complicating the Endovascular Treatment of Malignant Superior Vena Cava Syndrome: A Case Report and Literature Review. Semin Intervent Radiol. 2015;32(4):439-44. PMID 26622107
11. Ratzon R, Tamir S, Friehmann T, Livneh N, Dudnik E, Rozental A, et al. Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. J Thromb Thrombolysis. 2019;47(1):121-128. PMID 30255420
12. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022;40(5):492-516. PMID 34932393
13. Taylor JW, Schiff D. Metastatic epidural spinal cord compression. Semin Neurol. 2010;30(3):245-53. PMID 20577931
14. Warnock C, Hodson S, Tod A, Mills R, Crowther L, Buchanan J, et al. Improving care of patients with metastatic spinal cord compression. Br J Nurs. 2014;23(4):S14-8. PMID 24619048
15. Savage P, Sharkey R, Kua T, Schofield L, Richardson D, Panchmatia N, et al. Malignant spinal cord compression: NICE guidance, improvements and challenges. QJM. 2014;107(4):277-82. PMID 24336849
16. El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023;108(3):507-528. PMID 36545746
17. Fiordoliva I, Meletani T, Baleani MG, Rinaldi S, Savini A, Di Pietro Paolo M, et al. Managing hyponatremia in lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9(11):711-719. PMID 29344107
18. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023;41(16):3063-3071. PMID 37075273
19. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36(14):1443-1453. PMID 29461916
20. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073-4126. PMID 34724392
21. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016;22(24):6051-6060. PMID 27535979
22. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. PMID 31960755
23. Raikhelkar J, Uriel N. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 2019;34(3):303-306. PMID 30925516
24. Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discov. 2023;13(5):1100-1115. PMID 36815259
25. Voruganti Maddali IS, Cunningham C, McLeod L, Bahig H, Chaudhuri N, L M Chua K, et al. Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study. Lung Cancer. 2024;192:107822. PMID 38788551
26. Li S, Fan J, Liu J, Zhou J, Ren Y, Shen C, et al. Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients. Jpn J Clin Oncol. 2016;46(6):534-46. PMID 27052116
27. Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Shimada Y, et al. Risk assessments for broncho-pleural fistula and respiratory failure after lung cancer surgery by National Clinical Database Japan. Gen Thorac Cardiovasc Surg. 2019;67(3):297-305. PMID 30328066
28. Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, et al. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(7):839-849. PMID 30272503